Echo45 Advisors LLC Acquires 24 Shares of Eli Lilly and Company (NYSE:LLY)

Echo45 Advisors LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 658 shares of the company’s stock after acquiring an additional 24 shares during the period. Eli Lilly and Company makes up approximately 0.3% of Echo45 Advisors LLC’s holdings, making the stock its 26th biggest holding. Echo45 Advisors LLC’s holdings in Eli Lilly and Company were worth $384,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Lipe & Dalton purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at $27,000. Retirement Group LLC raised its holdings in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares during the period. Cornerstone Planning Group LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $33,000. Finally, Legacy Financial Group LLC purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at $35,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LLY shares. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Truist Financial reaffirmed a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded down $4.82 during midday trading on Thursday, hitting $745.95. The company’s stock had a trading volume of 1,701,145 shares, compared to its average volume of 3,067,708. The stock has a market capitalization of $708.77 billion, a price-to-earnings ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. The stock’s 50 day simple moving average is $764.03 and its 200 day simple moving average is $657.67. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same period last year, the business posted $2.09 earnings per share. As a group, research analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.